Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 200 g/l - injection, intravenous infusion - excipient ingredients: sodium; octanoate - hypoproteinaemia in the acutely ill patient albapure? 20 is administered when there are existing or anticipated clinical problems or complications from reduced oncotic pressure, and/or as an adjunct to diuretic therapy. shock: albapure? 20 may be used for the resuscitation of patients in shock due to acute loss of blood or plasma, but 4 - 5% human albumin is preferred when available. burns: extensive burns are followed by sequential shifts in the distribution of body water, salt and proteins resulting in hypovolaemic shock and circulatory failure.

United States - English - NLM (National Library of Medicine)

csl behring llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 25 g in 100 ml - albumin is indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. if there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated. albumin or albumin in either normal saline or dextrose is indicated to prevent marked hemoconcentration and to maintain appropriate electrolyte balance. albumin is indicated in those clinical situations usually associated with a low concentration of plasma protein and a resulting decreased circulating blood volume. although diuresis may occur soon after albumin administration has been instituted, best results are obtained if albumin is continued until the normal serum protein level is regained. albuminar® -25 may be contraindicated in patients with severe anemia or cardiac failure and in patients with a history of allergic reactions to human albumin.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

centrale afdeling voor fractionering - departement central de fractionnement s.p.r.l.-b.v.b.a. - albumin human 200 mg/ml - solution for infusion - 20 % - albumin human 200 mg/ml - albumin

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

octapharma benelux sa-nv - albumin human 200 g/l - solution for infusion - 20 % - albumin human 200 mg/ml - albumin

Ireland - English - HPRA (Health Products Regulatory Authority)

csl behring gmbh - human albumin solution - solution for infusion - 20, 200 gram(s)/litre - albumin

Israel - English - Ministry of Health

csl behring ltd., israel - albumin human - solution for infusion - albumin human 200 mg/ml - albumin - albumin - hypoalbuminemia (liver cirrhosis nephrosis) toxic processes ( pregnancy toxicosis, hyperbilirubinemia ) ,volume substitution therapy.

United States - English - NLM (National Library of Medicine)

csl behring ag - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 50 ml - since the oncotic pressure of alburx® 25, albumin (human) 25% solution is about four times higher than that of normal human serum, it will expand the plasma volume if interstitial water is available for an inflow through the capillary walls. however, many patients suffering from an acute volume deficit also have some degree of interstitial dehydration. in the absence of hyperhydration, the treatment of an acute volume deficit with alburx® 25 should therefore include isotonic electrolyte solutions with an albumin:electrolyte ratio of 1:3 or 1:4. by contrast, chronic volume deficits have usually been at least partially compensated for by the renal retention of sodium and water with some degree of tissue edema, and in these circumstances a trial with alburx® 25 only is indicated. in any case, an anemia of clinically relevant magnitude requires specific treatment, and the metabolic needs of the patient with respect to fluid and electrolytes must be cared for. the common causes of hypoproteinemia are protein-ca

United States - English - NLM (National Library of Medicine)

kedrion biopharma, inc. - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 10 g in 50 ml - emergency treatment of hypovolemic shock albuked 20 is hyperoncotic and on intravenous infusion will expand the plasma volume by an additional amount, three to four times the volume actually administered, by withdrawing fluid from the interstitial spaces, provided the patient is normally hydrated interstitially or there is interstitial edema.(1) if the patient is dehydrated, additional crystalloids must be given,(4) or alternatively, albumin (human) 5%, usp (albuked™ 5) should be used. the patient’s hemodynamic response should be monitored and the usual precautions against circulatory overload observed. the total dose should not exceed the level of albumin found in the normal individual; i.e., about 2 g per kg body weight in the absence of active bleeding. although albuked 5 is to be preferred for the usual volume deficits, albuked 20 with appropriate crystalloids may offer therapeutic advantages in oncotic deficits or in long-standing shock where treatment has been delayed.(2) removal of ascitic fluid from a

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 2.5 g in 50 ml - treatment of shock — plasmanate is indicated in the treatment of shock due to burns, crushing injuries, abdominal emergencies, and any other cause where there is a predominant loss of plasma fluids and not red blood cells. it is also effective in the emergency treatment of shock due to hemorrhage.(3,4) following the emergency phase of therapy, blood transfusions may be indicated depending on the severity of the blood loss. in infants and small children, plasmanate has been found to be very useful in the initial therapy of shock due to dehydration and infection. plasmanate is contraindicated for use in patients on cardiopulmonary bypass. severe hypotension has been reported in such patients when given plasma protein fraction.(4) plasma protein fraction is contraindicated in patients with severe anemia, congestive heart failure, or increased blood volume.

United States - English - NLM (National Library of Medicine)

grifols usa, llc - albumin human (unii: zif514rvzr) (albumin human - unii:zif514rvzr) - albumin human 12.5 g in 50 ml - for restoration and maintenance of circulating blood volume where hypovolemia is demonstrated and colloid use is appropriate. when hypovolemia is long standing and hypoalbuminemia exists accompanied by adequate hydration or edema, 20-25% albumin solutions should be used. [1,2,3] acute liver failure is a special situation in which both hypovolemia and hypoalbuminemia can be present. albutein 25% can be used in such cases. [1] albutein 25% may be of value in the treatment of shock or hypotension in renal dialysis patients. [1] preoperative dilution of blood using albumin and crystalloid can be used in cardiopulmonary bypass procedures. albumin also may be used in the priming fluid. [4,5,6] albutein 25% may be used to treat peripheral edema in patients with acute nephrosis who are refractory to cyclophosphamide, corticosteroid therapy or diuretics. [1,2,7] albutein 25% may be indicated for subjects with hypoalbuminemia who are critically ill and/or actively bleeding. when albumin deficit is the result of excessi